CSC today announced it has signed a purchase agreement to acquire Image Solutions, Inc., (ISI) a privately-held, global leader in regulatory submission management solutions and related implementation and outsourcing services for the Life Sciences sector. The anticipated acquisition will support the CSC Health Care strategic growth plan by expanding the company’s presence in the Life Sciences sector. Completion of the transaction is subject to ISI Shareholder approval and other standard conditions to closing; however, the transaction is expected to close before the end of the calendar year. Financial terms of the deal were not disclosed.
ISI’s offerings, such as eCTDXPress and ISIPublisher, combined with CSC’s enterprise content management offerings such as (FirstDoc and FirstPoint), will provide an integrated, end-to-end business solution for electronic regulatory submissions. Additional capabilities will also include integrated solutions that leverage ISI’s Life Sciences industry expertise with CSC’s established cloud/SaaS capabilities.
With more than 450 employees specializing in healthcare business process outsourcing (BPO), software design and integration, professional services solutions, a strong leadership team, and offices in the U.S., U.K., Germany, China, and Korea, ISI will enhance CSC’s capability to support existing customers and add a robust set of new clients. ISI’s operations in China, for example, will add 200 BPO and software development employees to CSC’s existing China organization. ISI’s Korean operations will also add to CSC’s global reach and growing presence in the Asian market.
The provision of high-value business process solutions will further highlight CSC’s commitment to both the global healthcare market and solving clients’ critical business challenges.
“CSC brings a comprehensive, experienced approach to analyzing, orchestrating, and securing new business opportunities in Life Sciences,” said Mark Roman, president, CSC Health Care Group. “We are pleased to add ISI’s deep healthcare and life sciences domain knowledge and history to the CSC family.”
“The combination of these companies will establish CSC as a strong player in healthcare IT,” said Jinsoo Kim, ISI founder, and CEO. “Both companies will make a compelling combination to yield an end to end drug submission management solution that will serve our clients very well.”